Role of Minocycline in First Episode Psychosis

Background:

There is increasing clinical, neuropsychological and imaging evidence that schizophrenia involves a progressive process at the time of the first episode and later in life. However, it is not clear which systems are affected nor in which parts of the brain. In two Stanley first episode cohorts at Manchester (Stirling et al, 2004,) and in a group of elderly patients with schizophrenia (Gabrovska-Johnson et al 2004), evidence of deterioration in visuo-spatial functions has been found. This implies a right-hemisphere pathology. Other evidence suggests that the initiation of schizophrenia may involve left-sided pathology (Lawrie et al 2002) so it could be that right hemisphere pathology may follow left and give rise to the deficits of chronic schizophrenia (Gabrovska-Johnson et al 2004). If so, early treatment with a neuroprotective agent might prevent the accumulation of deficit symptoms and cognitive impairment.

Minocycline is a tetracycline antibiotic with proven long-term high dose safety in humans, is routinely used to treat acne and rheumatoid arthritis demonstrating that it acts as a non-steroidal anti-inflammatory, as well as an antimicrobial drug. Minocycline, unlike tetracycline, crosses the blood-brain barrier. This and related compounds show neuroprotective properties in rat models of ischemic brain damage, in glutamate neurotoxicity in cell cultures and in a rat model of Huntington's disease in which it slowed progression (Chen et al, 2000; Yrjanheikki et al, 1999). Minocycline delays disease onset and extends survival in amyotrophic lateral sclerotic mice (Shan Zhu et al 2002).

Minocycline has various properties including inhibition of capsases, inhibition of microglial activation, reduced cyclooxygenase-2 expression and reduced prostaglandin E (2) formation. Furthermore, it inhibits the formation of inducible nitric oxide - a mechanism of glial activation. All these mechanisms have been implicated in schizophrenia. All these mechanisms have been implicated in schizophrenia.

Because of its broad spectrum of action, we consider minocycline is an important candidate molecule for the prevention of deterioration in schizophrenia. Based on the evidence so far we propose a randomised double blind placebo controlled study of minocycline added to treatment-as-usual (TAU) in first-episode psychosis.

Study Hypotheses:

• A neurodegenerative process, initially most marked in the left hemisphere, in late adolescence is responsible for the onset of schizophrenia in those at risk.
• Continuation of this process after onset and its extension to the right hemisphere causes accumulation of deficit symptoms and cognitive decline.
• Glutamate antagonism may enhance the antipsychotic effects of dopamine receptor blockade and prevent attenuation of efficacy with long-term treatment.

TREATMENT:

Minocycline is a widely available antibiotic given in doses of 50mg twice daily increasing to 200mgs per day. It has been used very widely and appears to be tolerated well. The study advisor, Dr. Serdar Dursun, has used doses of up to 200mg per day in the treatment of Huntington's disease (Denovan-Wright et al 2002).

It is widely available in Pakistan and Brazil and given in doses of 50mg twice daily increasing to 100mg twice daily (in total 200mg per day) (British National Formulary: BNF maximum dose 200mg per day). As per counselling recommendations in the British National Formulary: "minocycline medication should be swallowed whole with plenty of fluid while sitting or standing", to allow effective absorption. Patients will be counselled that 'the study medication should be swallowed whole with plenty of fluid while standing or sitting.'

Patients will be informed regarding reported side-effects as cited in the BNF these include; nausea, vomiting, diarrhoea, dysphagia, oesophageal irritation, anorexia, dizziness, tinnitus, vertigo, hypersensitivity reactions (rash, exfoliative dermatitis, urticaria, angioedema, anaphylaxis, pericarditis), headache, visual disturbances, hepatotoxicity, pancreatitis, antibiotic associated colitis, blood dyscrasias, exacerbation of systemic lupus erythematosus and myasthenia gravis, rarely photosensitivity, skin, teeth, conjunctiva, tears and sweat discoloration.

NUMBER OF PATIENTS:

Using data from the SOCRATES study, we are able to calculate that 40 patients per treatment arm will detect a group difference on the primary outcome measure, i.e, PANSS, giving a 85% chance of detecting a difference between treatment groups of 4 points. The power estimate is likely to be conservative as there are three treatment groups. The automated CSF measures will detect a 5% group difference with these sample sizes. A minimum of 52 completed patients will be necessary (26 completed patients per treatment group).

Study Advisors:

Prof Bill Deakin(design), Prof Serdar Dursun(scientific), Prof Shon Lewis (clinical), Dr John Stirling (cognition), Dr Paul Richardson (cognition), Prof Graham Dunn (analysis).